UnitedHealth Group (UNH)
250.89
+6.22 (2.54%)
NYSE · Last Trade: Aug 10th, 2:25 PM EDT
Detailed Quote
| Previous Close | 244.67 |
|---|---|
| Open | 244.79 |
| Bid | 250.99 |
| Ask | 251.00 |
| Day's Range | 244.37 - 251.08 |
| 52 Week Range | 234.60 - 630.73 |
| Volume | 10,185,909 |
| Market Cap | 228.31B |
| PE Ratio (TTM) | 10.51 |
| EPS (TTM) | 23.9 |
| Dividend & Yield | 8.840 (3.52%) |
| 1 Month Average Volume | 17,697,547 |
Chart
About UnitedHealth Group (UNH)
UnitedHealth Group is a leading diversified health and well-being company that provides a wide range of health care products and services. The company operates through two main segments: UnitedHealthcare, which offers health insurance and health services to individuals and businesses, and Optum, which delivers pharmacy care, health management, and technology solutions. UnitedHealth Group focuses on enhancing health care access, improving health outcomes, and optimizing costs through integrated care solutions and data-driven insights. With a commitment to innovation and quality, the company aims to help people live healthier lives while making the health care system work better for everyone. Read More
News & Press Releases
Megacap stocks dominate their sectors and their actions influence economies worldwide.
The flip side though is that their sheer size means they have less room for explosive growth as scale works against them.
Via StockStory · August 8, 2025
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 7.1% in the morning session after the company reported better-than-expected second-quarter 2025 financial results, beating revenue and earnings forecasts. The genomics company announced revenue of $39.77 million, a 10.4% increase year-over-year, which surpassed analysts' expectations by 7.6%. Its non-GAAP loss of $0.13 per share was also 21.5% narrower than anticipated. This performance was supported by a significant improvement in profitability, with the company's operating margin reaching negative 113%, a substantial improvement from negative 488% in the same quarter last year. The results suggest growing adoption of the company’s sequencing platforms, such as the Revio and Onso systems, which are used by researchers to analyze genomes with high accuracy.
Via StockStory · August 8, 2025
Shares of biotech company 10x Genomics (NASDAQ:TXG)
fell 5.5% in the morning session after the company reported strong second-quarter results that surpassed Wall Street's expectations for both revenue and profitability. The company announced revenue of $172.9 million, a 12.9% increase from the prior year and a significant 24% above analyst estimates. Profitability was a major bright spot, with GAAP earnings per share of $0.28, crushing the consensus forecast of a $0.37 loss per share. This impressive performance overshadowed a slightly cautious outlook for the upcoming third quarter, where the company's revenue guidance of $142 million came in just below analyst projections. Investors focused on the strong current performance, seeing the substantial earnings beat as a positive sign for the company's operational efficiency and market position.
Via StockStory · August 8, 2025
DOJ Requires Broad Divestitures, $1.1M Fine To Resolve UnitedHealth-Amedisys Merger Challenge: Retail Thinks It May Reduce Expected Synergiesstocktwits.com
Via Stocktwits · August 7, 2025
Shares of medical device company ICU Medical (NASDAQ:ICUI)
fell 10.5% in the morning session after the company reported second-quarter results where a significant earnings beat was overshadowed by a year-over-year revenue decline and concerning cash flow performance. The medical device company reported a GAAP profit of $1.43 per share, significantly reversing a loss from the prior year and handily beating analyst expectations. However, investors appeared to focus on the 8% year-over-year decline in revenue, which landed at $548.9 million, even though it slightly surpassed analyst forecasts. Furthermore, the company's free cash flow was a negative $8.49 million, a stark reversal from a positive $62.67 million in the same period last year, indicating pressure on its cash generation. Despite the company also issuing full-year profit guidance that was well ahead of Wall Street estimates, the revenue dip and negative cash flow seemingly weighed more heavily on investor sentiment.
Via StockStory · August 8, 2025
UnitedHealth will divest 164 healthcare locations and Amedisys will pay a $1.1 million penalty under a DOJ settlement resolving antitrust concerns over a $3.3 billion deal.
Via Benzinga · August 8, 2025
UnitedHealth is implementing artificial intelligence to improve efficiency.
Via The Motley Fool · August 8, 2025
Recent economic data from the United States has presented a nuanced picture of the nation's labor market, with a slight uptick in unemployment benefit applications alongside a significantly lower-than-expected nonfarm jobs report. While the increase in jobless claims remains within its recent range and is not immediately indicative of a
Via MarketMinute · August 7, 2025
The United States economy is currently grappling with a complex and often contradictory narrative, marked by recent weak payrolls data, a discernible slowdown in the labor market, and persistent inflationary pressures. This confluence of factors is sending ripples through the stock market, prompting increased volatility and a significant re-evaluation of
Via MarketMinute · August 7, 2025
Market volatility could increase in the months ahead, but these stocks should hold up well.
Via The Motley Fool · August 7, 2025
UnitedHealth Group has been hit with a series of bad news lately.
Via The Motley Fool · August 6, 2025
Shares of medical device company Artivion (NYSE:AORT)
jumped 3% in the morning session after investment firm Stifel raised its price target on the stock to $36 from $30, while maintaining a Buy rating. The adjustment followed Stifel's conversations with six physicians who utilized Artivion's aortic arch dissection repair stent (AMDS) after its FDA approval. The doctors reportedly offered positive commentary about the device, noting it simplified a complex procedure and enhanced results over existing treatments. This feedback reinforced Stifel's optimistic view on the technology's launch and its potential within what the firm estimated was a $150 million US market.
Via StockStory · August 6, 2025
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE)
fell 4.4% in the afternoon session after the company reported mixed second-quarter financial results, where a massive net loss overshadowed a revenue beat and raised guidance. The contract research organization posted revenues of $710.3 million, which exceeded analysts' expectations. However, investors focused on a staggering GAAP net loss of $374.9 million for the quarter. This loss resulted primarily from a non-cash goodwill impairment charge of $309.1 million. A goodwill impairment is an accounting adjustment made when the value of a company's assets declined. Fortrea attributed this charge to its own falling share price and market-driven interest rate increases. Further concerns arose from a weak book-to-bill ratio of 0.79x, which indicated the company secured less new business than it billed during the period.
Via StockStory · August 6, 2025
Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT)
jumped 9.5% in the afternoon session after the company reported better-than-expected second-quarter financial results and raised its full-year outlook. The medical device maker reported second-quarter earnings per share of $0.60 on revenue of $64.2 million, which beat Wall Street's expectations. The company's sales jumped 15% from the previous year, pushed by higher prices and a 7% increase in the number of products sold. Strong international sales for its Artegraft product also contributed to the growth. Looking ahead, LeMaitre lifted its full-year 2025 revenue forecast to $251 million and increased its earnings guidance, signaling management's confidence in continued strong performance.
Via StockStory · August 6, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN)
jumped 36.4% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year revenue forecast. The genetic testing firm announced revenue of $213.1 million, which sailed past analyst estimates of around $202 million. It also posted an adjusted profit of $0.05 per share, a significant turnaround from the minor loss that experts had predicted. A key driver for this outperformance was the company's hereditary cancer testing business, which grew 9% compared to the previous year. Bolstered by this momentum, Myriad Genetics lifted its full-year revenue guidance to a range of $818 million to $828 million and secured a new $200 million credit facility to fund its growth.
Via StockStory · August 6, 2025
Shares of health insurance company Clover Health (NASDAQ:CLOV) fell 20.3% in the afternoon session after the company reported mixed second-quarter results where rising medical costs and a wider-than-expected loss overshadowed strong revenue growth. The technology-focused insurer announced revenue of $477.6 million, which climbed past analyst forecasts, fueled by a 32% jump in Medicare Advantage membership. However, the company posted a net loss of $0.02 per share, a reversal from a profit in the same quarter last year and a miss on analyst expectations. Investors focused on the increase in the Insurance Benefits Expense Ratio (BER), a key metric showing the portion of premiums spent on medical care, which rose to 88.4%. Compounding the issue, Clover Health also raised its forecast for the full-year BER, signaling that these higher costs would likely persist. In response to the report, analysts at UBS cut their price target on the stock.
Via StockStory · August 6, 2025
Investors are interested in this company trading near its 52-week low.
Via The Motley Fool · August 6, 2025
Investors will not want to miss this update from the management team.
Via The Motley Fool · August 6, 2025
Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped.
Via The Motley Fool · August 6, 2025
While monthly jobs reports often grab headlines, savvy investors are increasingly looking beyond employment figures to a broader array of economic indicators for a more nuanced understanding of market health. Two such crucial metrics, Personal Consumption Expenditures (PCE) inflation and the Chicago Purchasing Managers' Index (PMI), are currently providing critical
Via MarketMinute · August 5, 2025
Shares of medical lens company STAAR Surgical (NASDAQ:STAA)
jumped 45.6% in the afternoon session after eye-care company Alcon announced a definitive agreement to acquire the company in an all-cash deal valued at approximately $1.5 billion. Under the terms of the deal, Alcon paid $28 in cash for each share of STAAR Surgical. This price marked a 51% premium to the company's closing stock price on the previous day. STAAR Surgical manufactured implantable lenses for vision correction, including its EVO family of Implantable Collamer® Lenses. The acquisition allowed Alcon to absorb a key player in the ophthalmic surgery space.
Via StockStory · August 5, 2025
Shares of healthcare services provider AdaptHealth Corp. (NASDAQ:AHCO) jumped 8.2% in the afternoon session after the company announced it secured a five-year exclusive agreement to become the sole provider of home medical equipment for a major national healthcare system. Under the agreement, AdaptHealth became the exclusive provider of home medical equipment and supplies for the system’s network of over 10 million members. The deal was structured primarily as a capitation payment model, a system where a provider receives a set fee per patient, which covered a mix of Medicare, Medicaid, and privately insured individuals. This significant contract news appeared to overshadow the company's second-quarter financial results, which were also released. The earnings report showed a decline in both net income and revenue compared to the same period last year, but investors seemingly prioritized the long-term growth prospects offered by the major partnership over the recent dip in financial performance.
Via StockStory · August 5, 2025
Concerns are mounting among financial analysts that the U.S. stock market may be entering an "overheated" phase, with equity valuations reaching levels that some deem unsustainable. This apprehension comes as major indices continue to flirt with record highs, prompting a critical debate about the market's current trajectory and its
Via MarketMinute · August 5, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.
Via Chartmill · August 5, 2025